Hemophilia A Treatments

Find Hemophilia A Treatments

Treatment Overview

Living with hemophilia A means your blood does not clot as well as it should because of missing or defective factor VIII, a clotting protein. Medicines can help replace the missing factor, prevent bleeding and lower the risk of complications. The right treatment depends on your health, lifestyle, medical history and how your body responds.  

Your care plan is personal, and your doctor will work with you to understand your options, track progress and adjust treatment as needed. 

Types of medicines 

There are several kinds of medicines used to treat hemophilia A: 

  • Clotting factor replacement therapy: These medicines replace the missing clotting factor VIII. They may be given when bleeding happens or on a regular schedule to help prevent bleeding. Examples include antihemophilic factor (Advate), octocog alfa (Kogenate FS) and moroctocog alfa (Xyntha). 
  • Extended half-life factor products: These work like regular factor VIII but last longer in the body, so fewer infusions may be needed. Examples include efmoroctocog alfa (Eloctate) and rurioctocog alfa pegol (Adynovate). 
  • Non-factor therapy: These medicines do not replace factor VIII directly but help the blood clot in other ways. An example is emicizumab (Hemlibra), which can be given under the skin instead of into a vein. 
  • Antifibrinolytics: These medicines help clots stay in place once they form. They are often used along with other therapies for dental work or surgery. An example is tranexamic acid (Lysteda). 

How doctors choose a medicine 

Your doctor will help decide which medicine to use based on how severe your hemophilia A is, your age, lifestyle and past reactions to treatment. Some people may do well with standard factor VIII infusions, while others may need extended half-life products or non-factor therapies for easier dosing. If inhibitors (antibodies that block factor VIII) develop, special medicines may be needed. 

Monitoring and follow-up 

Regular checkups are important. Blood tests help show whether you are getting the right amount of medicine and if your body is responding well. Doctors also look for side effects, check for inhibitors and ask about any bleeding episodes. Follow-up visits help make sure your treatment is safe and effective. 

Adjusting therapy over time 

Treatment plans can change. A child may begin with infusions only during bleeds and later move to regular preventive therapy. Adults may switch to newer medicines that need fewer doses. If bleeding happens too often, or if inhibitors develop, your care team may adjust or “escalate” therapy. 

Working together with lifestyle changes 

Medicines work best when combined with healthy habits. Protecting joints, staying active with safe exercises like swimming and avoiding high-risk activities that may cause injuries are all important. Sometimes surgery, physical therapy or dental procedures may be needed, and medicines are adjusted around those times. 

Precautions and safety 

Different medicines have different risks, and it is important to know what to watch for: 

  • Risk of inhibitors (antibodies): The most common and serious complication of hemophilia A treatment is the development of inhibitors, which are antibodies that block factor VIII. These make treatment less effective and can make bleeding harder to control. 
  • Pregnancy and organ health: During pregnancy, both dosing and medicine choice may need careful adjustment under specialist care. Antifibrinolytics such as tranexamic acid (Lysteda) may not be safe in people with kidney disease, and clotting factor use in people with liver disease often requires close monitoring. 
  • Drug interactions: Some antifibrinolytics can interact with other medicines that affect blood clotting, which may raise the risk of complications. Emicizumab (Hemlibra) is generally safe but may increase the risk of serious clotting problems if combined with high doses of certain bypassing agents, so doctors monitor these situations closely. 
  • Side effects: Most side effects are mild and may include infusion-site pain, headache, joint discomfort or low fever. Allergic reactions can occur with factor VIII products, and in rare cases medicines may cause serious clotting problems that may require emergency treatment. Regular follow-up helps detect these issues early so treatment can remain safe and effective. 

Always tell your care team about allergies, health conditions and all the medicines or supplements you take. It’s also important to take medicines exactly as prescribed. Skipping doses or stopping suddenly can lead to bleeding episodes. If cost, side effects or remembering doses is hard, talk to your doctor—there are often solutions. 

Medications for Hemophilia A

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Hemophilia A.

Found 9 Approved Drugs for Hemophilia A

Hemlibra

Generic Name
Emicizumab

Hemlibra

Generic Name
Emicizumab
Form: Injection
Method of administration: Subcutaneous
FDA approval date: November 16, 2017
HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. HEMLIBRA is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. ( 1 )

Desmopressin Acetate

Brand Names
DDAVP, Desmoda

Desmopressin Acetate

Brand Names
DDAVP, Desmoda
Form: Injection, Spray, Tablet, Solution
Method of administration: Intravenous, Subcutaneous, Nasal, Oral
FDA approval date: May 01, 1984
Classification: Factor VIII Activator
Hemophilia A DDAVP Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. DDAVP will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. DDAVP will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. DDAVP is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try DDAVP in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand's Disease (Type I) DDAVP Injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand's disease (Type I) with factor VIII levels greater than 5%. DDAVP will often maintain hemostasis in patients with mild to moderate von Willebrand's disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. DDAVP will usually stop bleeding in mild to moderate von Willebrand's patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrand's disease patients who are least likely to respond are those with severe homozygous von Willebrand's disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of DDAVP to ensure that adequate levels are being achieved. DDAVP is not indicated for the treatment of severe classic von Willebrand's disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. (See WARNINGS. ) Diabetes Insipidus DDAVP Injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. DDAVP is ineffective for the treatment of nephrogenic diabetes insipidus. DDAVP is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery.

Sevenfact

Generic Name
VIIa

Sevenfact

Generic Name
VIIa
Form: Kit
Method of administration: Intravenous
FDA approval date: December 10, 2020
SEVENFACT [coagulation factor VIIa (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors. Limitation of Use: SEVENFACT is not indicated for the treatment of patients with congenital Factor VII deficiency. SEVENFACT [coagulation factor VIIa (recombinant)-jncw] is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors ( 1 ). Limitation of Use: SEVENFACT is not indicated for treatment of congenital factor VII deficiency.

FEIBA

Generic Name
Anti-Inhibitor

FEIBA

Generic Name
Anti-Inhibitor
Form: Kit
FDA approval date: January 31, 1986
FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for: Control and prevention of bleeding episodes Perioperative management Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation factor VIII or coagulation factor IX. FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for: Control and prevention of bleeding episodes. Perioperative management. Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to factor VIII or factor IX. ( 1 )

Alhemo

Generic Name
Concizumab

Alhemo

Generic Name
Concizumab
Form: Injection
Method of administration: Subcutaneous
FDA approval date: February 19, 2025
Classification: Tissue Factor Pathway Inhibitor Antagonist
Alhemo is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors, hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors Alhemo is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:, hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors, hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors ( 1 )
Showing 1-5 of 9
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances